• Published On : Feb-2015 |
  • Pages : 141 Pages |
  • Format :

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

     4.2.1 Growing prevalence of diabetes

     4.2.2 Technological advancements in human insulin delivery devices

     4.2.3 Increasing awareness among people towards diabetes care

4.3 Impact Analysis of Market Drivers

4.4 Market Restraints

     4.4.1 Uneven pricing and limited access to human insulin in emerging countries

     4.4.2 Strict regulatory requirements for drug approval

4.5 Impact Analysis of Market Restraints

4.6 Market Trends

     4.6.1 Increasing usage of insulin pens for administration of human insulin

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Type

6.1 Traditional Human Insulin

6.2 Modern Human Insulin

Chapter 7 Market Size and Forecast of Traditional Human Insulin by Type

7.1 Short-acting Human Insulin

7.2 Intermediate-acting Human Insulin

7.3 Premixed Human Insulin

Chapter 8 Market Size and Forecast of Modern Human Insulin by Type

8.1 Rapid-acting Human Insulin

8.2 Long-acting Human Insulin

8.3 Premixed Human Insulin

Chapter 9 Market Size and Forecast by Disease

9.1 Type 1 Diabetes

9.2 Type 2 Diabetes

Chapter 10 Market Size and Forecast by Brand

10.1 Traditional Human Insulin Brand

10.2 Modern Human Insulin Brand

Chapter 11 Market Size and Forecast by Geography

11.1 North America

     11.1.1 Scenario in the U.S.

     11.1.2 Scenario in Canada

11.2 Europe

     11.2.1 Scenario in Germany

     11.2.2 Scenario in France

     11.2.3 Scenario in the U.K.

11.3 Asia Pacific

     11.3.1 Scenario in Japan

     11.3.2 Scenario in China

     11.3.3 Scenario in India 

Chapter 12 Pipeline Drugs for Diabetes Treatment 

12.1 Drugs Under Development for Diabetes Treatment

Chapter 13 Competitive Scenario 

13.1 Competitive Benchmarking

Chapter 14 Company Profiles

14.1 Novo Nordisk A/S

     14.1.1 Company overview

     14.1.2 Products and services

     14.1.3 Financial performance

     14.1.4 Key developments

14.2 Eli Lilly and Company

     14.2.1 Company overview

     14.2.2 Products and services

     14.2.3 Financial performance

     14.2.4 Key developments

14.3 Sanofi

     14.3.1 Company overview

     14.3.2 Products and services

     14.3.3 Financial performance

     14.3.4 Key developments

14.4 Biocon

     14.4.1 Company overview

     14.4.2 Products and services

     14.4.3 Financial performance 

     14.4.4 Key developments

14.5 Tonghua Dongbao Pharmaceutical Co., Ltd.

     14.5.1 Company overview

     14.5.2 Products and services

     14.5.3 Financial performance

     14.5.4 Key developments

14.6 ADOCIA

     14.6.1 Company overview

     14.6.2 Products and services

     14.6.3 Financial performance

     14.6.4 Key developments

14.7 Wockhardt

     14.7.1 Company overview

     14.7.2 Products and services

     14.7.3 Financial performance

     14.7.4 Key developments

14.8 Julphar

     14.8.1 Company overview

     14.8.2 Products and services

     14.8.3 Financial performance

     14.8.4 Key developments

14.9 Merck & Co., Inc.

     14.9.1 Company overview

     14.9.2 Products and services

     14.9.3 Financial performance

     14.9.4 Key developments

14.10 Pfizer, Inc.

     14.10.1 Company overview

     14.10.2 Products and services

     14.10.3 Financial performance

     14.10.4 Key developments

14.11 Bristol-Myers Squibb Company

     14.11.1 Company overview

     14.11.2 Products and services

     14.11.3 Financial performance

     14.11.4 Key developments

14.12 GlaxoSmithKline Plc

     14.12.1 Company overview

     14.12.2 Products and services

     14.12.3 Financial performance

     14.12.4 Key developments

14.13 Oramed Pharmaceuticals, Inc.

     14.13.1 Company overview 

     14.13.2 Products and services

     14.13.3 Financial performance

     14.13.4 Key developments


List of Tables

TABLE 1 Market snapshot: Human insulin market, 2014 and 2020

TABLE 2 Drivers for human insulin market: Impact analysis

TABLE 3 Restraints for human insulin market: Impact analysis

TABLE 4 Global human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 5 Global human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 6 Global human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 7 Global human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 8 Global traditional human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 9 Global traditional human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 10 Global modern human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 11 Global modern human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 12 Global short-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 13 Global short-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 14 Global intermediate-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 15 Global intermediate-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 16 Global premixed human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 17 Global premixed human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 18 Global rapid-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 19 Global rapid-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 20 Global long-acting human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 21 Global long-acting human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 22 Global premixed human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 23 Global premixed human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 24 Global type 1 diabetes human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 25 Global type 1 diabetes human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 26 Global type 2 diabetes human insulin market size, by region, 2010 – 2013 (USD million)

TABLE 27 Global type 2 diabetes human insulin market size, by region, 2014 – 2020 (USD million)

TABLE 28 Global traditional human insulin market size, by brand, 2010 – 2013 (USD million)

TABLE 29 Global traditional human insulin market size, by brand, 2014 – 2020 (USD million)

TABLE 30 Global modern human insulin market size, by brand, 2010 – 2013 (USD million)

TABLE 31 Global modern human insulin market size, by brand, 2014 – 2020 (USD million)

TABLE 32 The North American human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 33 The North American human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 34 The U.S. human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 35 The U.S. human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 36 The U.S. traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 37 The U.S. traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 38 The U.S. modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 39 The U.S. modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 40 The Canadian human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 41 The Canadian human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 42 The Canadian traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 43 The Canadian traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 44 The Canadian modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 45 The Canadian modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 46 The European human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 47 The European human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 48 The German human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 49 The German human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 50 The German traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 51 The German traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 52 The German modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 53 The German modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 54 The French human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 55 The French human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 56 The French traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 57 The French traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 58 The French modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 59 The French modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 60 The U.K. human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 61 The U.K. human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 62 The U.K. traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 63 The U.K. traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 64 The U.K. modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 65 The U.K. modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 66 The Asia Pacific human insulin market size, by country, 2010 – 2013 (USD million)

TABLE 67 The Asia Pacific human insulin market size, by country, 2014 – 2020 (USD million)

TABLE 68 The Japanese human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 69 The Japanese human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 70 The Japanese traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 71 The Japanese traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 72 The Japanese modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 73 The Japanese modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 74 The Chinese human insulin market size, by type, 2010 – 2013 (USD million) 

TABLE 75 The Chinese human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 76 The Chinese traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 77 The Chinese traditional human insulin market size, by type, 2014 – 2020 (USD million) 

TABLE 78 The Chinese modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 79 The Chinese modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 80 The Indian human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 81 The Indian human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 82 The Indian traditional human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 83 The Indian traditional human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 84 The Indian modern human insulin market size, by type, 2010 – 2013 (USD million)

TABLE 85 The Indian modern human insulin market size, by type, 2014 – 2020 (USD million)

TABLE 86 Major pipeline drugs for diabetes treatment

TABLE 87 Major product segments of Novo Nordisk A/S

TABLE 88 Major product segments of Eli Lilly and Company 

TABLE 89 Major product categories of Sanofi

TABLE 90 Major product categories of Biocon

TABLE 91 Major product categories of Tonghua Dongbao Pharmaceutical Co., Ltd.

TABLE 92 Major product categories of Adocia

TABLE 93 Major product categories of Wockhardt

TABLE 94 Major product categories of Julphar

TABLE 95 Major product categories of Merck & Co., Inc.

TABLE 96 Major product categories of Pfizer, Inc.

TABLE 97 Major product categories of Bristol-Myers Squibb Company

TABLE 98 Major product categories of GlaxoSmithKline Plc

TABLE 99 Major product categories of Oramed Pharmaceuticals, Inc.


List of Figures 

FIG. 1 Human insulin market: Porter’s five forces analysis

FIG. 1 Major types of human insulin

FIG. 2 Major types of insulin delivery devices

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010 and 2030 (million)

FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 (%)

FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 (%)

FIG. 6 Global human insulin market share, by region, by value, 2013

FIG. 7 Global human insulin market share, by type, by value, 2013

FIG. 8 Global traditional human insulin market share, by region, by value, 2013

FIG. 9 Global modern human insulin market share, by region, by value, 2013

FIG. 10 Global short-acting human insulin market share, by region, by value, 2013

FIG. 11 Global intermediate-acting human insulin market share, by region, by value, 2013 

FIG. 12 Global premixed human insulin market share, by region, by value, 2013

FIG. 13 Global rapid-acting human insulin market share, by region, by value, 2013

FIG. 14 Global long-acting human insulin market share, by region, by value, 2013

FIG. 15 Global premixed human insulin market share, by region, by value, 2013

FIG. 16 Global type 1 diabetes human insulin market share, by region, by value, 2013

FIG. 17 Global type 2 diabetes human insulin market share, by region, by value, 2013

FIG. 18 Global traditional human insulin market share, by brand, by value, 2013

FIG. 19 Global modern human insulin market share, by brand, by value, 2013

FIG. 20 The North American human insulin market share, by country, by value, 2013

FIG. 21 The U.S. human insulin market share, by type, by value, 2013

FIG. 22 The U.S. traditional human insulin market share, by type, by value, 2013

FIG. 23 The U.S. modern human insulin market share, by type, by value, 2013

FIG. 24 The Canadian human insulin market share, by type, by value, 2013

FIG. 25 The Canadian traditional human insulin market share, by type, by value, 2013

FIG. 26 The Canadian modern human insulin market share, by type, by value, 2013

FIG. 27 The European human insulin market share, by country, by value, 2013

FIG. 28 The German human insulin market share, by type, by value, 2013

FIG. 29 The German traditional human insulin market share, by type, by value, 2013

FIG. 30 The German modern human insulin market share, by type, by value, 2013

FIG. 31 The French human insulin market share, by type, by value, 2013

FIG. 32 The French traditional human insulin market share, by type, by value, 2013

FIG. 33 The French modern human insulin market share, by type, by value, 2013

FIG. 34 The U.K. human insulin market share, by type, by value, 2013

FIG. 35 The U.K. traditional human insulin market share, by type, by value, 2013

FIG. 36 The U.K. modern human insulin market share, by type, by value, 2013

FIG. 37 The Asia Pacific human insulin market share, by country, by value, 2013

FIG. 38 The Japanese human insulin market share, by type, by value, 2013

FIG. 39 The Japanese traditional human insulin market share, by type, by value, 2013

FIG. 40 The Japanese modern human insulin market share, by type, by value, 2013

FIG. 41 The Chinese human insulin market share, by type, by value, 2013 

FIG. 42 The Chinese traditional human insulin market share, by type, by value, 2013

FIG. 43 The Chinese modern human insulin market share, by type, by value, 2013

FIG. 44 The Indian human insulin market share, by type, by value, 2013

FIG. 45 The Indian traditional human insulin market share, by type, by value, 2013

FIG. 46 The Indian modern human insulin market share, by type, by value, 2013

FIG. 47 Competitive benchmarking of human insulin manufacturing companies

FIG. 48 Novo Nordisk’s net sales and net profit, 2011 – 2013 (USD million)

FIG. 49 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million)

FIG. 50 Sanofi’s net sales and net income, 2011 – 2013 (USD million)

FIG. 51 Biocon’s revenue and profit, 2012 – 2014 (USD million)

FIG. 52 Tonghua Dongbao Pharmaceutical Co., Ltd.’s total revenue and net income, 2011 – 2013 (USD million)

FIG. 53 Wockhardt’s revenue and net income, 2011 – 2013 (USD million)

FIG. 54 Julphar’s sales and profit, 2011 – 2013 (USD million)

FIG. 55 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)

FIG. 56 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)

FIG. 57 Bristol-Myers Squibb Company’s total revenue and net earnings, 2011 – 2013 (USD million)

FIG. 58 GlaxoSmithKline Plc’s turnover and profit, 2011 – 2013 (USD million)